Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Cash from Financing Activities (2016 - 2025)

Avanos Medical's Cash from Financing Activities history spans 11 years, with the latest figure at -$27.4 million for Q4 2024.

  • For Q4 2024, Cash from Financing Activities rose 76.11% year-over-year to -$27.4 million; the TTM value through Dec 2024 reached -$49.1 million, up 47.88%, while the annual FY2025 figure was -$37.0 million, 24.64% up from the prior year.
  • Cash from Financing Activities for Q4 2024 was -$27.4 million at Avanos Medical, down from -$16.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $105.7 million in Q1 2022 and bottomed at -$114.7 million in Q4 2023.
  • The 5-year median for Cash from Financing Activities is -$10.2 million (2022), against an average of -$11.2 million.
  • The largest annual shift saw Cash from Financing Activities crashed 68200.0% in 2020 before it soared 52950.0% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$68.3 million in 2020, then skyrocketed by 62.23% to -$25.8 million in 2021, then grew by 15.12% to -$21.9 million in 2022, then tumbled by 423.74% to -$114.7 million in 2023, then surged by 76.11% to -$27.4 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Cash from Financing Activities are -$27.4 million (Q4 2024), -$16.0 million (Q3 2024), and -$5.0 million (Q2 2024).